TransMedics Group, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025: USD 82.66 M

TransMedics Group, Inc. EBITDA is USD 82.66 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 752.25% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • TransMedics Group, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 9.70 M, a -149.55% change year over year.
  • TransMedics Group, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -19.57 M, a -51.13% change year over year.
  • TransMedics Group, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -40.05 M, a 80.09% change year over year.
  • TransMedics Group, Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -22.24 M, a -25.40% change year over year.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)